Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

ABSTRACT: Prostate cancer (PCa) is the second most common cause of cancer-related mortality in men in the United States. The androgen receptor (AR) and the physiological pathways it regulates are central to the initiation and progression of PCa. As a member of the nuclear steroid receptor family, it is a transcription factor with three distinct functional domains (ligand-binding domain [LBD], DNA-binding domain [DBD], and transactivation domain [TAD]) in its structure. All clinically approved drugs for PCa ultimately target the AR-LBD. Clinically active drugs that target the DBD and TAD have not yet been developed due to multiple factors. Despite these limitations, the last several years have seen a rise in the discovery of molecules that could successfully target these domains. This review aims to

SUBMITTER: Elshan NGRD 

PROVIDER: S-EPMC6608750 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature